Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company.
40 
Let's personalize your content